| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
17,796,000 |
| Market
Cap: |
140.59(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.65 - $25.14 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.1 |
| Insider 6 Months : 8.1 |
| Insider 3/6 Months : 16.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Selecta Biosciences is a clinical-stage biopharmaceutical company. Co.'s ImmTOR® platform encapsulates rapamycin, also known as sirolimus, a Food and Drug Administration approved immunomodulator, in biodegradable nanoparticles ImmTOR is designed to induce antigen-specific immune tolerance. By combining ImmTOR with antigens of interest, Co.'s immune tolerance platform restores self-tolerance to auto-antigens in autoimmune diseases, amplify the ability of biologics (including gene therapies) and mitigate the formation of anti-drug antibodies against biologic drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
30,000 |
30,000 |
342,094 |
1,786,647 |
| Total Buy Value |
$205,797 |
$205,797 |
$4,430,843 |
$9,610,669 |
| Total People Bought |
1 |
1 |
2 |
2 |
| Total Buy Transactions |
1 |
1 |
15 |
33 |
| Total Shares Sold |
0 |
0 |
39,263 |
88,715 |
| Total Sell Value |
$0 |
$0 |
$680,704 |
$1,604,228 |
| Total People Sold |
0 |
0 |
6 |
6 |
| Total Sell Transactions |
0 |
0 |
13 |
17 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barabe Timothy C |
Director |
– • – |
2025-12-04 |
4 |
B |
$6.86 |
$205,797 |
D/D |
30,000 |
54,366 |
2.39 |
- |
|
| English Emily |
Chief Operations Officer |
• – – |
2025-11-28 |
4 |
OE |
$3.30 |
$24,750 |
D/D |
7,500 |
62,726 |
|
- |
|
| Singer Michael |
Director |
– • – |
2025-11-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
53,533 |
|
- |
|
| English Emily |
Chief Operations Officer |
• – – |
2025-05-12 |
4 |
OE |
$3.30 |
$24,750 |
D/D |
7,500 |
55,226 |
|
- |
|
| English Emily |
Chief Operations Officer |
• – – |
2025-04-15 |
4 |
OE |
$3.30 |
$24,750 |
D/D |
7,500 |
47,726 |
|
- |
|
| Springer Timothy A |
Director |
– • • |
2025-04-11 |
4 |
B |
$10.77 |
$391,455 |
I/I |
36,338 |
656,513 |
2.25 |
3% |
|
| Springer Timothy A |
Director |
– • • |
2025-04-11 |
4 |
B |
$10.77 |
$69,074 |
D/D |
6,412 |
8,643,685 |
3.92 |
3% |
|
| Springer Timothy A |
Director |
– • • |
2025-04-10 |
4 |
B |
$10.43 |
$508,751 |
I/I |
48,595 |
620,175 |
2.25 |
7% |
|
| Springer Timothy A |
Director |
– • • |
2025-04-10 |
4 |
B |
$10.43 |
$89,773 |
D/D |
8,575 |
8,637,273 |
3.92 |
7% |
|
| Springer Timothy A |
Director |
– • • |
2025-04-09 |
4 |
B |
$9.43 |
$393,947 |
I/I |
41,782 |
571,580 |
2.25 |
-4% |
|
| Springer Timothy A |
Director |
– • • |
2025-04-09 |
4 |
B |
$9.43 |
$69,517 |
D/D |
7,373 |
8,628,698 |
3.92 |
-4% |
|
| Springer Timothy A |
Director |
– • • |
2025-03-20 |
4 |
B |
$15.59 |
$855,593 |
D/D |
54,889 |
8,621,325 |
3.92 |
-19% |
|
| Springer Timothy A |
Director |
– • • |
2025-03-19 |
4 |
B |
$14.97 |
$302,962 |
D/D |
20,234 |
8,566,436 |
3.92 |
-13% |
|
| Springer Timothy A |
Director |
– • • |
2025-03-18 |
4 |
B |
$14.42 |
$212,599 |
D/D |
14,740 |
8,546,202 |
3.92 |
-6% |
|
| Springer Timothy A |
Director |
– • • |
2025-01-14 |
4 |
B |
$18.00 |
$72,396 |
D/D |
4,022 |
8,531,462 |
3.92 |
-49% |
|
| Springer Timothy A |
Director |
– • • |
2025-01-13 |
4 |
B |
$16.86 |
$293,958 |
D/D |
16,945 |
8,527,440 |
3.92 |
-50% |
|
| Jewell Christopher M |
Chief Scientific Officer |
• – – |
2025-01-10 |
4 |
OE |
$3.23 |
$29,070 |
D/D |
9,000 |
62,490 |
|
- |
|
| Davis Blaine |
Chief Financial Officer |
• – – |
2025-01-06 |
4 |
S |
$16.83 |
$67,800 |
D/D |
(4,028) |
94,811 |
|
42% |
|
| Miljkovic Milos |
Chief Medical Officer |
• – – |
2025-01-06 |
4 |
S |
$16.83 |
$15,957 |
D/D |
(948) |
35,393 |
|
42% |
|
| English Emily |
Chief Operations Officer |
• – – |
2025-01-06 |
4 |
S |
$16.83 |
$15,250 |
D/D |
(906) |
40,226 |
|
42% |
|
| Jewell Christopher M |
Chief Scientific Officer |
• – – |
2025-01-06 |
4 |
S |
$16.83 |
$21,646 |
D/D |
(1,286) |
53,490 |
|
42% |
|
| Brunn Carsten |
President and CEO |
• • – |
2025-01-06 |
4 |
S |
$16.83 |
$146,575 |
D/D |
(8,708) |
204,096 |
|
42% |
|
| Kurtoglu Metin |
Chief Technology Officer |
• – – |
2025-01-06 |
4 |
S |
$16.83 |
$41,374 |
D/D |
(2,458) |
62,258 |
|
42% |
|
| Davis Blaine |
Chief Financial Officer |
• – – |
2025-01-03 |
4 |
S |
$16.72 |
$66,235 |
D/D |
(3,961) |
98,839 |
|
38% |
|
| Miljkovic Milos |
Chief Medical Officer |
• – – |
2025-01-03 |
4 |
S |
$16.72 |
$15,585 |
D/D |
(932) |
36,341 |
|
38% |
|
335 Records found
|
|
Page 1 of 14 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.18 (17.56%) 
